Company overview
UCB is a global biopharmaceutical company focused on neurology and immunology, developing treatments for epilepsy, rheumatoid arthritis, and rare neurological disorders. Key products include CIMZIA® for inflammatory diseases, VIMPAT® and KEPPRA® for epilepsy, and emerging therapies like BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®. The company invests about a quarter of its revenue in R&D, with operations in nearly 40 countries and headquarters in Brussels, Belgium.
Inspired by Patients. Driven by Science. is listed in the NovaPharmaNews Supplier Hub as a CDMO & Manufacturing partner serving United States & Americas. Core focus areas include ucb biopharma, neurology drugs, immunology treatments, epilepsy therapies, cimzia supplier.
Industry categories: CDMO & Manufacturing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.ucb.com
- Categories
- CDMO & Manufacturing
- Markets served
- United States & Americas
- Keywords
- ucb biopharma, neurology drugs, immunology treatments, epilepsy therapies, cimzia supplier
Products & technologies
Therapeutic areas
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What are UCB's main therapeutic areas and key products?
- UCB focuses on neurology (epilepsy, rare disorders) and immunology (rheumatoid arthritis, psoriasis). Top products include CIMZIA®, VIMPAT®, KEPPRA®, BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®.
- What is UCB's R&D focus and capabilities?
- UCB invests ~25% of revenue in cutting-edge research for unmet needs in neurology and immunology, with a robust pipeline including brain-penetrant small molecules and exploration of gene therapy.
- Where does UCB operate geographically?
- UCB has ~7,500 employees in nearly 40 countries, global HQ in Brussels, Belgium, and U.S. HQ in Atlanta, Georgia.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
